ARTHEx Biotech S.L., founded in 2019 and based in Paterna, Spain, is a spin-off from the University of Valencia focused on the development of antisense RNA treatments for genetic diseases. The company leverages a team with extensive expertise in drug discovery and the role of microRNAs in neuromuscular disorders. Supported by a network of esteemed scientific and clinical advisors, ARTHEx Biotech aims to advance its innovative product pipeline to address unmet medical needs in the treatment of genetic conditions.
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
Alex Health AB, based in Stockholm, is an innovative digital therapeutics company focused on using artificial intelligence and psychological principles to promote behavioral change. Founded in 2017, Alex is developing a second-generation behavioral change application aimed at assisting one billion individuals in overcoming detrimental habits and enhancing their mental health. The company leverages its proprietary AI platform to create CE-marked software medical devices classified as Class I apps, which serve various therapeutic areas. Alex has recently secured funding from the King founders through their Sweet Studio fund, furthering its mission to transform the support clinicians provide to patients seeking to improve their health outcomes. The company operates from Norrsken House and Sweet Studio, both located in central Stockholm.
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Ribbon Biolabs GmbH builds and develops synthesis of long deoxyribonucleic acid (DNA) molecule. It creates and explores genetic solutions by the throughput synthesis of DNA of unprecedented length. The company was founded in 2018 and is based in Vienna, Austria.
Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor designed to target a critical microRNA that regulates harmful changes in the heart resulting from stress or injury. Cardior Pharmaceuticals is positioned as a planned academic spin-off, emphasizing innovative approaches to address significant cardiovascular health challenges.
Oncoinvent AS develops antibody based therapeutics for cancer patients. It offers Radspherin, an alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities; radiotherapeuti; radioimmunotherapeutic; and immunotherapeutic products. The company was founded in 2010 and is based in Oslo, Norway.
SAGA Diagnostics AB is a Swedish company specializing in molecular genetic testing and services aimed at healthcare and biopharmaceutical sectors, as well as academic institutions. Founded in 2016 and based in Lund, SAGA focuses on personalized cancer genomics and disease monitoring. The company provides cutting-edge services such as cancer medicine, gene mutation analysis, and both tissue and non-invasive liquid biopsies, including blood samples. SAGA's proprietary technology enables the ultrasensitive quantification of circulating tumor DNA, achieving a detection limit of 0.001%. This advanced capability allows for the accurate detection of actionable mutations, patient stratification, and monitoring of treatment responses, thereby enhancing the management of cancer therapies and providing patients with greater peace of mind.
Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player in the funding of healthcare and biotechnology in Europe.
Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.
CardioMech AS is a Norwegian company specializing in the development of catheter-based systems for mitral valve repair. Founded in 2015 and headquartered in Trondheim, the company offers a transcatheter alternative to traditional cardiac surgery, focusing on the placement of artificial chords for the mitral valve. This innovative technology aims to provide new therapeutic options for patients suffering from severe, symptomatic degenerative mitral regurgitation, particularly those experiencing issues such as prolapse or flail. By enabling less invasive procedures, CardioMech seeks to improve treatment outcomes for individuals with structural heart diseases.
Gesynta Pharma AB is a pharmaceutical company based in Solna, Sweden, focused on developing selective inhibitors of microsomal prostaglandin E synthase-1 (mPGES-1) to address chronic inflammatory conditions and related diseases. The company conducts research on the role of arachidonic acid and aims to create oral treatments for cardiovascular diseases and cancer. Its lead product, GS-248, is a highly potent mPGES-1 inhibitor that has entered clinical phase development. By targeting the pro-inflammatory enzyme mPGES-1, Gesynta Pharma seeks to provide safe and effective anti-inflammatory and pain-relieving pharmaceuticals to improve patient outcomes in various serious diseases. Founded in 2017, the company is committed to advancing innovative therapies in the field of inflammation.
Oncoinvent AS develops antibody based therapeutics for cancer patients. It offers Radspherin, an alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities; radiotherapeuti; radioimmunotherapeutic; and immunotherapeutic products. The company was founded in 2010 and is based in Oslo, Norway.
Neuro Event Labs is a Finnish medical technology growth company. The company’s main product monitors epilepsy patients at home and in hospital. Accurate epilepsy seizure data is collected, analyzed and relayed to the patient’s physician, who makes individual treatment decisions based on the reports. The solution has been developed on close cooperation with leading Finnish hospitals.
Pipeline Therapeutics Inc. develops and commercializes small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair. The company’s lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of earlier stage programs, including PIPE-307, focused on remyelination and axonal repair to address a range of neurological disorders, including multiple sclerosis. The company was founded in 2017 and is based in San Diego, California.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.
SAGA Diagnostics AB is a Swedish company specializing in molecular genetic testing and services aimed at healthcare and biopharmaceutical sectors, as well as academic institutions. Founded in 2016 and based in Lund, SAGA focuses on personalized cancer genomics and disease monitoring. The company provides cutting-edge services such as cancer medicine, gene mutation analysis, and both tissue and non-invasive liquid biopsies, including blood samples. SAGA's proprietary technology enables the ultrasensitive quantification of circulating tumor DNA, achieving a detection limit of 0.001%. This advanced capability allows for the accurate detection of actionable mutations, patient stratification, and monitoring of treatment responses, thereby enhancing the management of cancer therapies and providing patients with greater peace of mind.
Nisonic is a medical technology company that develops products that will allow physicians to diagnose and monitor increased intracranial pressure (ICP) in an easier and cost-effective way. Nisonic will offer an accurate non-invasive ICP monitoring system for emergency departments, EMC, intensive care and critical care units. Early detection of ICP and intervention are critical to lowering death and disability rates, but currently only invasive methods are available to monitor increased ICP. Invasive methods are associated with risk of bleeding and infections, are only available at larger hospitals and have a considerable cost. While invasive intracranial pressure monitoring has been available for many years, non-invasive measurement has so far not been accurate enough. Nisonic is developing an software that analyzes ultrasound images of the eye to monitor increased ICP, and that can be integrated into ultrasound devices on the market, enabling widespread use among physicians and other health workers.
AttgeNO
Venture Round in 2018
AttgeNO is a pharmaceutical company developing treatments for acute life-threatening conditions.